Joint patent for using the BRCA1 gene as a therapy for cardiovascular disease

February 10, 2012

St. Michael's Hospital and King Saud University have received their first joint U.S. patent to use the BRCA1 gene as a therapy for cardiovascular disease.

Dr. Subodh Verma, a at St. Michael's, and Dr. Mohammed Al-Omran, a vascular surgeon at the largest university in Saudi Arabia, are named as inventors on patent US 8, 110,185 B2 issued Feb. 7.

Obtaining the patent is an initial step in realizing the potential of this innovative approach to treating one of the leading causes of death in Canada,

Dr. Verma's team published three papers in 2011, in Nature Communications, the and Gene Therapy, showing how the BRCA1 and 2 genes, which normally suppresses the growth of breast and ovarian tumours, also protect the heart.

Following a heart attack, mice with the mutated had a three-to-five times higher rate of death. This was largely due to the development of profound heart failure and poor DNA damage repair, leading to larger and more severe heart attacks.

Dr. Verma said the mutated BRCA1 gene may prevent in that is essential to recovery after a heart attack.

"The patent is also significant because it demonstrates how collaborative research between St. Michael's and King Saud University can help speed the transfer of medical discoveries from the laboratory bench to patient bedsides," said Dr. Arthur Slutsky, vice-president of research.

St. Michael's and King Saud jointly own the invention. The hospital has an agreement with the university and the inventors on how to share royalties. The hospital also has a commercialization partner, PARTEQ innovations, the technology transfer arm of Queen's University.

Explore further: Breast cancer and heart disease may have common roots

Related Stories

Recommended for you

How our cells use mother's and father's genes

September 28, 2016

Researchers at Karolinska Institutet and Ludwig Institute for Cancer Research have characterized how and to what degree our cells utilize the gene copies inherited from our mother and father differently. At a basic level ...

Questions, concerns about 'three-parent' baby

September 28, 2016

The surprise announcement that a healthy baby boy was born from a new technique mixing the DNA of two women and a man raises as many questions—scientific and ethical—as it settles, experts said Wednesday.

Regulatory RNA essential to DNA damage response

September 26, 2016

Stanford researchers have found that a tumor suppressor known as p53 is stabilized by a regulatory RNA molecule called DINO. The interaction helps a cell respond to DNA damage and may play a role in cancer development and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.